Harrison S, Piliang M, Bergfeld W, et al. Hair disorders. In: Cleveland Clinic, ed. Current Clinical Medicine (Second Edition). Second Edi. Philadelphia: W.B. Saunders; 2010:289–293.e1. https://doi.org/10.1016/B978-1-4160-6643-9.00042-4.

Nilforoushzadeh MA, Golparvaran M. YekaninejadMS: Assessment of quality of life and self-esteem in male patients with androgenetic alopecia before and after hair transplantation. J Cosmet Dermatol. 2023;22(8):2283–7. https://doi.org/10.1111/jocd.15716.

Article  PubMed  Google Scholar 

Wang G, Wang Z, Shen Y, Hou X, Su L, Chen W, et al. Treatment of androgenetic alopecia by exosomes secreted from hair papilla cells and the intervention effect of LTF. J Cosmet Dermatol. 2023. https://doi.org/10.1111/jocd.15873.

Article  PubMed  Google Scholar 

•• Li K, Sun Y, Liu S, Zhou Y, Qu Q, Wang G, et al. The AR/miR-221/IGF-1 pathway mediates the pathogenesis of androgenetic alopecia. Int J Biol Sci. 2023;19(11):3307–3323. https://doi.org/10.7150/ijbs.80481. This found that miR-221 significantly suppressed hair growth and the proliferation of dermal papilla cells and dermal sheath cells in AGA patients. Interestingly, miR-221 and AR were mainly co-located in the same part of the hair follicle, making it a novel biomarker and potential therapeutic target for treating AGA.

Zhao B, Li J, Chen Q, Yang N, Bao Z, Hu S, et al. A treatment combination of IGF and EGF promotes hair growth in the Angora rabbit. Genes (Basel). 2020;12(1):24. https://doi.org/10.3390/genes12010024.

Article  CAS  PubMed  Google Scholar 

Willems A, Sinclair R. Alopecias in humans: Biology, pathomechanisms and emerging therapies. Vet Dermatol. 2021;32(6):596-e159. https://doi.org/10.1111/vde.13014.

Article  PubMed  Google Scholar 

Redmond L, Limbu S, Farjo B, Messenger A, Higgins C. Male pattern hair loss: Can developmental origins explain the pattern? Exp Dermatol. 2023. https://doi.org/10.1111/exd.14839.

Article  PubMed  Google Scholar 

Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2002;45:S70–80.

Article  Google Scholar 

Ramos PM, Miot HA. Female pattern hair loss: A clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529–43.

Article  PubMed  PubMed Central  Google Scholar 

Ramos P, Melo D, Radwanski H, De Almeida R, Miot H. Female pattern hair loss: Therapeutic update An Bras Dermatol. 2023;S0365–0596(23):00053–63. https://doi.org/10.1016/j.abd.2022.09.006.

Article  Google Scholar 

Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81:648–9.

Article  PubMed  Google Scholar 

• Lemes LR, Melo D, De Oliveira D, De La-Rocque M, Zompero C, Ramos P. Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far? Dermatol Ther. 2020; 33(6):e13950. https://doi.org/10.1111/dth.13950. This article pointed out the use of minoxidil in several pediatric hair diseases. Even when used topically, dermatologists should be aware of potential risks of systemic absorption. In particular situations, OMX in very low doses may be considered. To date, there are no guidelines regarding the ideal dose or minimum age for using the drug topically or systemically.

Verma K, Tegta GR, Verma G, Gupta M, Negi A, Sharma R. A study to compare the efficacy of platelet-rich plasma and minoxidil therapy for the treatment of androgenetic alopecia. Int J Trichology. 2019;11(2):68–79.

Goren A, McCoy J, Prodrugs L. In European handbook of dermatological treatments. Katsambas AD, Lotti TM, Dessinioti C, D’Erme AM (eds.) Springer, Berlin, Heidelberg 2015.

Bansal S, Lau A. Human liver cytosolic sulfotransferase 2A1-dependent dehydroepiandrosterone sulfation assay by ultra-high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2016;20(120):261–9. https://doi.org/10.1016/j.jpba.2015.12.029.

Article  CAS  Google Scholar 

Goto R, Oaku Y, Sasak F, Kubota C, Deguchi S, Kadowaki R, et al. Effects of skin environmental changes by steam towel, ethanol, l-menthol and carpronium on the drug behavior in the minoxidil nanoparticles-applied mice. Yakugaku Zasshi. 2022;142(9):1015–20. https://doi.org/10.1248/yakushi.22-00103.

Article  CAS  PubMed  Google Scholar 

Kikuchi S, Fujita Y, Onodera M, Fujino Y, Inoue Y. Prolonged hypotension induced by ingesting a topical minoxidil solution: Analysis of minoxidil and its metabolites. Acute Med Surg. 2016;3(4):384–7. https://doi.org/10.1002/ams2.196.

Article  PubMed  PubMed Central  Google Scholar 

Anderson R, Kudlacek P, Clemens D, et al. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1–3):53–67. https://doi.org/10.1016/s0009-2797(97)00120-8.

Article  CAS  PubMed  Google Scholar 

Goren A, Sharma A, Dhurat R, Shapiro J, Sinclair R, Situm M, et al. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31(6):e12741. https://doi.org/10.1111/dth.12741.

• Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Moreno-Arrones OM, Ortega-Quijano D, Fernandez-Nieto D, et al. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther. 2020;33:e14106. This systematic review and pooled-analysis showed low dose OM is a safe and well-tolerated treatment for hair loss with a lower adverse effect rate than standard doses.

Modha J, Pathania Y. Comprehensive review of oral minoxidil in alopecia. J Cosmet Dermatol. 2022;21(11):5527–31. https://doi.org/10.1111/jocd.15324.

Article  PubMed  Google Scholar 

Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: A comprehensive review. J Dermatolog Treat. 2022;33(4):1896–906. https://doi.org/10.1080/09546634.2021.1945527.

Article  CAS  PubMed  Google Scholar 

Ramírez-Marín HA, Tosti A. Role of oral minoxidil in patterned hair loss Indian Dermatol Online J. 2022;13(6):729–33. https://doi.org/10.4103/idoj.idoj_246_22.

Article  PubMed  Google Scholar 

Jha AK, Sonthalia S, Zeeshan MD, Vinay K. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia. J Am Acad Dermatol. 2020;83:1491–3.

Pirmez R, Salas-Callo CI. Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82:e21–2.

Article  PubMed  Google Scholar 

Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–46. https://doi.org/10.1016/j.jaad.2020.06.1009.

Article  CAS  PubMed  Google Scholar 

Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: An open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345–57. https://doi.org/10.1007/s13555-020-00448-x.

Article  PubMed  Google Scholar 

Sharma AN, Michelle L, Juhasz M, Ramos PM, Mesinkovska NA. Low-dose oral minoxidil as treatment for non-scarring alopecia: A systematic review. Int J Dermatol. 2020;59(8):1013–9. https://doi.org/10.1111/ijd.14933.

Article  PubMed  Google Scholar 

Vahabi-Amlashi A, Layegh P, Kiafar B, Hoseininezhad M, Abbaspour M, Khaniki S, et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. Dermatol Ther. 2021;34(6):e15131. https://doi.org/10.1111/dth.15131.

Therianou A, Vincenzi C, Tosti A, et al. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? J Am Acad Dermatol. 2022;86:429–31. https://doi.org/10.1016/j.jaad.2020.04.027.

Article  CAS  PubMed  Google Scholar 

Jerjen R, Koh WL, Sinclair R, Bhoyrul B. Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184:977–8.

Article  CAS  PubMed  Google Scholar 

John J, Sinclair R. Systemic minoxidil for hair disorders in pediatric patients: A safety and tolerability review. Int J Dermatol. 2023;62(2):257–9. https://doi.org/10.1111/ijd.16373.

Article  CAS  PubMed  Google Scholar 

Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C’s of oral therapy. Dermatol Ther. 2018;31(6):e12707. https://doi.org/10.1111/dth.12707.

•• Kim SR, Craiglow BG. Treatment of traction alopecia with oral minoxidil treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022;23:112–113. https://doi.org/10.1016/j.jdcr.2022.03.023. Considering the limited data regarding the therapeutic options for tractional alopecia, this article indicted that response to oral minoxidil in this patient suggests that it may be a promising treatment for patients for tractional alopecia.

Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res. 2017;6:1650. https://doi.org/10.12688/f1000research.11775.1.

Beach R, McDonald K, Barrett B, et al. Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series. J Am Acad Dermatol. 2021;84(3):761–3. https://doi.org/10.1016/j.jaad.2020.10.032.

Article  CAS  PubMed  Google Scholar 

Feaster B, Onamusi T, Cooley J, McMichael A. Oral minoxidil use in androgenetic alopecia and telogen effluvium. Arch Dermatol Res. 2023;315(2):201–5. https://doi.org/10.1007/s00403-022-02331-5.

Article  CAS  PubMed  Google Scholar 

Bhoyrul B, Asfour L, Lutz G, Mitchell L, Jerjen R, Sinclair R, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335–42. https://doi.org/10.1001/jamadermatol.2021.3676.

Article  PubMed  Google Scholar 

Martora F, Vastarella M, Fattore D, Patri A, Fabbrocini G, Cantelli M. Oral minoxidil for chemotherapy-induced alopecia. Skin Appendage Disord. 2022;8(6):508–10. https://doi.org/10.1159/000525463.

Article  PubMed  PubMed Central  Google Scholar 

Sinclair RD. Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–9. https://doi.org/10.1111/ijd.13838.

Article  CAS  PubMed  Google Scholar 

Kim SR, Craiglow BG. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022;23:112–3. https://doi.org/10.1016/j.jdcr.2022.03.023.

Article  PubMed  PubMed Central  Google Scholar 

Mostafa DH, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A. Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: A randomized, single-blind controlled study. J Pharm Pharm Sci. 2021;24:191–199. https://doi.org/10.18433/jpps31456

Choi N, Shin S, Song SU, Sung J. Minoxidil promotes hair growth through stimulation of growth factor release from adipose-derived stem cells. Int J Mol Sci. 2018;19(3):691. https://doi.org/10.3390/ijms19030691.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knitlova J, Doubkova M, Plencner M, Vondrasek D, Eckhardt A, Ostadal M, et al. Minoxidil decreases collagen I deposition and tissue-like contraction in clubfoot-derived cells: A way to improve conservative treatment of relapsed clubfoot? Connect Tissue Res. 2021;62(5):554–69. https://doi.org/10.1080/03008207.2020.1816992.

Article  CAS  PubMed  Google Scholar 

Hummadi A, Gany S, Hadi N, et al. Evaluation of the effect of topically applied methylsulfonylmethane and their combination with minoxidil solution for improvement of hair growth in male mice. Wiad Lek. 2022;75(11 pt 2):2744–2751. https://doi.org/10.36740/WLek202211206.